Journal de Pharmacie de Belgique - 101ème année n° 1 - mars 2019 15
Références
1 Zuberbier et al. Economic burden
of inadequate management of
allergic diseases in the European
Union: a GA(2) LEN review. Allergy.
2014;69(10):1275-9
2 Mehuys E. et al. Self-medication
in persistent rhinitis: overuse of
decongestants in half of the patients.
J Allergy Clin Immunol Pract.
2014;2(3):313-9
3 Tan et al. The Burden of Rhinitis
and the Impact of Medication
Management within the Community
Pharmacy Setting. J Allergy Clin
Immunol Pract. 2018;6(5):1717-1725
4 Cruz A.A et al. Common
characteristics of upper and lower
airways in rhinitis and asthma: ARIA
update, in collaboration with GA(2)
LEN. Allergy 2007; 62: 1-41
5 Cornwell S., Foulon V. Zelfzorgadvies
in de apotheek-deel 2. ACCO
Uitgeverij, 16 oktober 2018
6 NHG-Standaard Allergische en nietallergische
rinitis (tweede herziening
2018). Disponible via : www.nhg.
org/standaarden/samenvatting/
allergische-en-niet-allergischerhinitis
7 Bousquet J et al. Aria workshop
group, World Health Organization.
Allergic rhinitis and its impact on
asthma. Allergy 2008;63 (suppl 86)
8 Greiner A.N. et al. Allergic Rhinitis.
Lancet. 2011;378(9809):2112-22
9 Juel-Berg N. et al. Intranasal
corticosteroids compared with oral
antihistamines in allergic rhinitis:
A systematic review and metaanalysis.
Am J Rhinol Allergy.
2017;31(1):19-28
10 Carr W. et al. A novel intranasal
therapy of azelastine with fluticasone
for the treatment of allergic
rhinitis. J Allergy Clin Immunol.
2012;129(5):1282-1289
11 Bousquet J. et al. Advances in
pharmacotherapy for the treatment
of allergic rhinitis; MP29-02 (a
novel formulation of azelastine
hydrochloride and fluticasone
propionate in an advanced delivery
system) fills the gaps. Expert Opin
Pharmacother. 2015;16(6):913-28
12 Azélastine + fluticasone - Dymista°.
Rhinite allergique : en rester à une
monothérapie par voie nasale Rev.
Prescrire 2015;35(380):412
13 Han D. et al. A multicenter
randomized double-blind 2-week
comparison study of azelastine nasal
spray 0.1% versus levocabastine
nasal spray 0.05% in patients with
moderate-to-severe allergic rhinitis.
ORL J Otorhinolaryngol Relat Spec.
2011;73(5):260-5
14 Décongestionnants
vasoconstricteurs et risques
cardiovasculaires : compléter les
RCP ne suffit pas. Rev. Prescrire
2011;31:660
15 AFMPS. Conseils pour un bon usage
des médicaments vasoconstricteurs
par voie nasale utilisés en cas de
rhume. 08/03/2017. Disponible
via : www.afmps.be/fr/news/
conseils_pour_un_bon_usage_des_
medicaments_vasoconstricteurs_
par_voie_nasale_utilises_en_cas_de
16 Hermelingmeier K.E. et al. Nasal
irrigation as an adjunctive treatment
in allergic rhinitis: A systematic
review and meta-analysis. Am J
Rhinol Allergy. 2012;26(5):e119–e125.
Disponible via : www.ncbi.nlm.nih.
gov/pmc/articles/PMC3904042/pdf/
zrie119.pdf
17 CBIP. Fiche de transparence –
La rhino-conjonctivite allergique
saisonnière (Rhume des foins). 2008.
Disponible via : www.cbip.be/tf/FR/
TF_RDF.pdf
18 CYBELE Geneesmiddelen voor
en tijdens zwangerschap en
borstvoeding. 2019. Disponible via :
www.cybele.be/
19 Church D.S. et al. Allergic rhinitis:
impact, diagnosis, treatment and
management. Clinical pharmacist
2016;8(8):249-255
20 AFMPS. Conditions de passage au
statut OTC pour les corticostéroïdes
nasaux. Disponible via : www.
afmps.be/sites/default/files/
conditions_de_passage_au_statut_
otc_pour_les_corticosteroides_
nasaux_-_final-_17_03_01.pdf
21 UZLeuven. Allergie, informatie voor
patiënten. Disponible via : https://
www.uzleuven.be/sites/default/files/
brochures/Allergie.pdf
22 NHS choices. Hay fever. Disponible
via : www.nhs.uk/conditions/
hay-fever/
23 Bousquet J. et al. MACVIA-ARIA
Sentinel NetworK for allergic rhinitis
(MASK-rhinitis): the new generation
guideline implementation. Allergy
2015;70(11):1372-1392. Disponible
via : https://onlinelibrary.wiley.com/
doi/full/10.1111/all.12686
24 Portnoy J. et al. Environmental
assessment and exposure control
of dust mites: a practice parameter.
Ann Allergy Asthma immunol
2013;111:465-507. Disponible
via : www.annallergy.org/article/
S1081-1206(13)00718-7/fulltext
25 Nurmatov U. et al. House dust mite
avoidance measures for perennial
allergic rhinitis: an updated
Cochrane systematic review. Allergy
2012;67(2):158-65
26 Arroyave WD. et al. Impermeable
dust mite covers in the primary
and tertiary prevention of allergic
disease: a meta-analysis. Ann Allergy
Asthma Immunol. 2014;112(3):237-48
27 https://airallergy.sciensano.be/nl
28 Bousquet J. et al. MACVIA Clinical
Decision Algorithm in Allergic
Rhinitis in adolescents and adults.
Journal of Allergy and Clinical
Immunology 2016;138(2):367-374.
Disponible via : www.jacionline.
org/article/S0091-6749(16)30148-8/
fulltext
29 Bousquet J. et al. MASK 2017:
ARIA digitally-enabled, integrated,
person-centred care for rhinitis
and asthma multimorbidity using
real-world-evidence. Clinical and
Translational Allergy2018;8:45.
Disponible via : https://ctajournal.
biomedcentral.com/articles/10.1186/
s13601-018-0227-6
Pratique
/
/
/www.ncbi.nlm.nih
/
/
/
/www.nhg
/
/
/nl
/www.jacionline
/ctajournal
/